Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

Drugs that Destabilize Microtubules

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...

Metastasis

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Cancer

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A novel G13-RAPGEF2-RAP1 signaling pathway critical for platelet adhesion and aggregation.

Blood·2026

Same author

Evaluation of 3 commercial assays for the measurement of tissue factor activity in human plasma.

Research and practice in thrombosis and haemostasis·2026

Same author

Tissue factor detection in mouse tissues by western blotting using commercial antibodies.

Research and practice in thrombosis and haemostasis·2026

Same author

Comparison of changes in blood cells and hemostatic biomarkers in mouse xenograft models of acute myeloid leukemia and acute promyelocytic leukemia.

Research and practice in thrombosis and haemostasis·2026

Same author

Potential Mechanisms Underlying Bleeding During Infection With Hemorrhagic Fever Viruses.

Arteriosclerosis, thrombosis, and vascular biology·2025

Same author

New light on the activators of factor XI in venous thromboembolism.

Lancet (London, England)·2025

Same journal

Splenomegaly in primary antiphospholipid syndrome without accompanying portal hypertension or comorbidity.

Pathophysiology of haemostasis and thrombosis·2011

Same journal

The influence of tissue factor and tissue factor pathway inhibitor polymorphisms on thrombin generation in stable coronary artery disease.

Pathophysiology of haemostasis and thrombosis·2011

Same journal

Impact of chemotherapy on thrombin generation and on the protein C pathway in breast cancer patients.

Pathophysiology of haemostasis and thrombosis·2011

Same journal

The effect of chronic cadmium toxicity on blood pressure and plasma viscosity.

Pathophysiology of haemostasis and thrombosis·2011

Same journal

Serum and saliva sialic acid in periodontitis patients with and without cardiovascular disease.

Pathophysiology of haemostasis and thrombosis·2011

Same journal

Plasma tissue factor levels and salivary tissue factor activities of periodontitis patients with and without cardiovascular disease.

Pathophysiology of haemostasis and thrombosis·2011

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 26, 2026

Generation of Lymphocytic Microparticles and Detection of their Proapoptotic Effect on Airway Epithelial Cells

Generation of Lymphocytic Microparticles and Detection of their Proapoptotic Effect on Airway Epithelial Cells

Published on: February 20, 2015

Microparticles and cancer.

Chirag Amin¹, Nigel Mackman, Nigel S Key

¹Department of Medicine and Program in Hemostasis and Thrombosis, Carolina Cardiovascular Biology Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA.

Pathophysiology of Haemostasis and Thrombosis

|January 30, 2009

Summary

This summary is machine-generated.

Cancer patients have a higher risk of blood clots due to cancer-associated microparticles (MPs). Further research is needed to confirm their role and explore therapeutic targeting of these procoagulant vesicles.

More Related Videos

Tracking miRNA Release into Extracellular Vesicles using Flow Cytometry

Tracking miRNA Release into Extracellular Vesicles using Flow Cytometry

Published on: October 6, 2023

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment

Published on: May 14, 2019

Related Experiment Videos

Last Updated: Jun 26, 2026

Generation of Lymphocytic Microparticles and Detection of their Proapoptotic Effect on Airway Epithelial Cells

Generation of Lymphocytic Microparticles and Detection of their Proapoptotic Effect on Airway Epithelial Cells

Published on: February 20, 2015

Tracking miRNA Release into Extracellular Vesicles using Flow Cytometry

Tracking miRNA Release into Extracellular Vesicles using Flow Cytometry

Published on: October 6, 2023

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment

Published on: May 14, 2019

Area of Science:

Oncology
Hematology
Biochemistry

Background:

Cancer is recognized as a prothrombotic state, increasing the risk of both arterial and venous thromboemboli.
Circulating microparticles (MPs), derived from activated or apoptotic cells, are implicated in cancer-related thrombosis, but their causal role remains debated.

Purpose of the Study:

To review the current understanding of the origin and procoagulant role of circulating MPs in cancer.
To discuss the clinical associations between MPs and malignancies.
To highlight the need for prospective studies to validate the functional significance of MPs in cancer outcomes.

Main Methods:

Literature review of existing studies on cancer-associated microparticles.
Analysis of the procoagulant properties of MPs.
Examination of clinical data linking MPs to cancer and thromboembolic events.

Main Results:

Microparticles are vesicles originating from cancer cells and host cells.
MPs possess procoagulant activity and are clinically associated with various malignancies.
Current evidence on the direct causal link between MPs and clinical thromboembolic events in cancer is inconclusive.

Conclusions:

Circulating microparticles are a key area of investigation in cancer-related thrombosis.
Future research should focus on prospective studies to establish the functional importance of MPs in cancer.
If proven significant, microparticles may represent a future therapeutic target for managing cancer-related thromboembolic complications.